Novo-Nordisk (NVO)

Add to Watchlists Create an Alert
168.49 -0.43  -0.25%   NYSE May 24, 9:36AM BATS Real time Currency in USD

Novo-Nordisk SG&A Expense Quarterly:

1.088B for March 31, 2013
View Full Chart

Novo-Nordisk SG&A Expense Quarterly Chart

    Novo-Nordisk Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 1.088B
    Dec. 31, 2012 1.276B
    Sept. 30, 2012 1.051B
    June 30, 2012 1.002B
    March 31, 2012 1.007B
    Dec. 31, 2011 1.100B
    Sept. 30, 2011 1.003B
    June 30, 2011 1.042B
    March 31, 2011
    Dec. 31, 2010 999.08M
    Sept. 30, 2010 991.13M
    June 30, 2010 809.94M
    March 31, 2010 846.49M
    Dec. 31, 2009 918.18M
    Sept. 30, 2009 823.86M
    June 30, 2009 842.40M
    March 31, 2009 785.41M
    Dec. 31, 2008 918.86M
    Sept. 30, 2008 721.15M
       
    June 30, 2008 806.08M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    NVO SG&A Expense Quarterly Benchmarks

    Companies
    Eli Lilly and Company 1.652B
    Sanofi 2.729B
    AstraZeneca 2.595B

    NVO SG&A Expense Quarterly Rankings

    Overall 97th percentile
    195 of 8009
    Sector 96th percentile
    22 of 687 in Healthcare
    Industry 99th percentile
    2 of 248 in Biotechnology

    NVO SG&A Expense Quarterly Range, Past 5 Years

    Minimum 721.15M Sep 2008
    Maximum 1.276B Dec 2012
    Average 948.97M